Analysis Tools
growth/size/body
weight loss
(
J:261967
)
|
• mice injected repeatedly with the toll-like receptor 9 ligand unmethylated cytosine guanine dinucleotide containing single-stranded DNA (CpG) show a marked weight loss and poor general condition
|
|
• CpG challenged mice develop more pronounced hepatomegaly than in wild-type mice
|
|
• CpG-challenged mice develop more pronounced splenomegaly than in wild-type mice
|
hematopoietic system
|
• CpG challenged mice show a higher increase in CD45+ cell counts in the spleen, which is associated with a higher number of B cells and monocytes/macrophages
|
pancytopenia
(
J:261967
)
|
• mice injected repeatedly with CpG develop more peripheral pancytopenia than in controls, except for white blood cells
|
|
• CpG-challenged mice exhibit hemophagocytes in the bone marrow
|
|
• CpG challenged mice show a higher increase in CD45+ cell counts in the spleen, which is associated with a higher number of B cells and monocytes/macrophages
|
|
• CpG challenged mice show a higher increase in CD45+ cell counts in the spleen, which is associated with a higher number of B cells and monocytes/macrophages
|
|
• mice injected repeatedly with CpG show more pronounced disruption of the normal spleen architecture with nucleated cell infiltration into the red pulp than in wild-type mice
|
|
• CpG-challenged mice develop more pronounced splenomegaly than in wild-type mice
|
|
• CpG challenged mice develop a more severe macrophage activation syndrome than in controls
• mice injected with a blocking monoclonal anti-IL-18R antibody before each CpG injection show attenuation of the severity of macrophage activation syndrome manifestations, with corrected weight loss, higher white blood cell, red blood cell, and platelet counts, lower ferritin levels and ALT activity, reduced splenomegaly, decreased circulating levels of IFN-gamma and CXCL9
• mice injected with a monoclonal anti-IFN-gamma antibody before each CpG injection show attenuation of the severity of macrophage activation syndrome manifestations, with reduced weight loss, splenomegaly, total spleen counts, anemia, plasma ferritin levels and ALT activity
|
homeostasis/metabolism
|
• CpG challenged mice, both with a single injection or repeated injections, exhibit more increased CXCL9 plasma levels than wild-type mice
|
|
• CpG challenged mice, both with a single injection or repeated injections, exhibit increased plasma IFN-gamma levels compared to wild-type mice
|
|
• CpG challenged mice, both with a single injection or repeated injections, exhibit increased serum levels of free IL-18
|
|
• mice injected repeatedly with CpG show an increase in plasma alanine transaminase (ALT) activity
|
|
• mice injected with CpG show higher ferritin levels than controls
|
immune system
| N |
• mice do not exhibit a spontaneous proinflammatory phenotype and appear healthy, with normal numbers of spleen T and B cells, dendritic cells, monocytes/macrophages, and neutrophils
|
|
• CpG challenged mice show a higher increase in CD45+ cell counts in the spleen, which is associated with a higher number of B cells and monocytes/macrophages
|
|
• CpG-challenged mice exhibit hemophagocytes in the bone marrow
|
|
• CpG challenged mice show a higher increase in CD45+ cell counts in the spleen, which is associated with a higher number of B cells and monocytes/macrophages
|
|
• CpG challenged mice show a higher increase in CD45+ cell counts in the spleen, which is associated with a higher number of B cells and monocytes/macrophages
|
|
• mice injected repeatedly with CpG show more pronounced disruption of the normal spleen architecture with nucleated cell infiltration into the red pulp than in wild-type mice
|
|
• CpG-challenged mice develop more pronounced splenomegaly than in wild-type mice
|
|
• CpG challenged mice develop a more severe macrophage activation syndrome than in controls
• mice injected with a blocking monoclonal anti-IL-18R antibody before each CpG injection show attenuation of the severity of macrophage activation syndrome manifestations, with corrected weight loss, higher white blood cell, red blood cell, and platelet counts, lower ferritin levels and ALT activity, reduced splenomegaly, decreased circulating levels of IFN-gamma and CXCL9
• mice injected with a monoclonal anti-IFN-gamma antibody before each CpG injection show attenuation of the severity of macrophage activation syndrome manifestations, with reduced weight loss, splenomegaly, total spleen counts, anemia, plasma ferritin levels and ALT activity
|
|
• CpG challenged mice, both with a single injection or repeated injections, exhibit more increased CXCL9 plasma levels than wild-type mice
|
|
• CpG challenged mice, both with a single injection or repeated injections, exhibit increased plasma IFN-gamma levels compared to wild-type mice
|
|
• CpG challenged mice, both with a single injection or repeated injections, exhibit increased serum levels of free IL-18
|
|
• CpG challenged mice show lower total lymphoid follicle area than in wild-type mice
|
liver/biliary system
|
• CpG challenged mice develop more pronounced hepatomegaly than in wild-type mice
|
